Genta Inc (GNTA.O: Quote, Profile, Research) said the U.S. Food and Drug Administration has extended the review of the appeal the company had filed against the health regulator's refusal to approve its cancer treatment, Genasense.
Genta now expects a final decision on the drug later in the current quarter. It had earlier expected a final decision in the fourth quarter of 2007.
The biopharmaceutical company said this review is related to the use of the drug, combined with chemotherapy, in patients with relapsed or refractory chronic lymphocytic leukemia, a kind of blood cancer. (Reporting by Varsha Tickoo in Bangalore; Editing by Pratish Narayanan)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.